Skip to content
Est. 1998 proudly celebrating 27 years of standing behind American companies
American Origin Unverified This profile is unclaimed and has not been independently reviewed. Claim & get verified

BIOVIE INC. (BIVI)

$2.19 +3.79% NASDAQ: BIVI · 15-min delayed
  • CARSON CITY, Nevada
  • Public · NASDAQ: BIVI
  • 13 employees
  • Founded 2007
$10.3MMarket cap
$0Revenue · FY2016
-$17.5MNet income
13Employees
BIVINASDAQ
2014IPO

About BIOVIE INC.

BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.

This profile is unclaimed. An authorized representative can claim it free to control the page and activate the embeddable Verified badge.

Reported figures

Financial summary

Revenue FY2016
$0
Net income
-$17.5M
Total assets
$21.6M
Market cap
$10.3M

Source: SEC EDGAR · updated Jun 8, 2026

Multi-year

Revenue & profit trend

Revenue Net income
FY 2026

Financial statements

Income statement

Revenue
$0
Operating expenses
$22.7M
Operating income
-$22.7M
Net income
-$22.1M
EPS (basic)
$-3.05
EPS (diluted)
$-3.05

Balance sheet

Total assets
$14.3M
Current assets
$13.6M
Total liabilities
$4.0M
Current liabilities
$3.8M
Shareholders’ equity
$10.3M

Cash flow

Operating cash flow
-$19.0M
Investing cash flow
$8.6M
Financing cash flow
$10.5M
Net cash flow
$0

Statements via Polygon.io (SEC filings)

NASDAQ: BIVI
$2.19 +3.79%

15-minute delayed · data by Polygon.io

Past year · hover for prices

$0.96 $7.55

52-week range

Market cap
$10.3M
EPS (diluted)
$-3.05
Shares outstanding
4.7M
Open
Day range
Prev close
Volume
IPO date
Jan 14, 2014

Biovie Inc. (BIVI) Stock Price

  • Reported a net loss of $17.5M in FY2016.
  • Trading 71% below its 52-week high.

Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.

No reviews yet. Be the first to review BIOVIE INC..

Write a review
Newsroom

News about BIOVIE INC.

News & sentiment via Polygon.io

FAQ

Biovie Inc.: frequently asked questions

Is Biovie Inc. an American company?

Biovie Inc. is a US-based company headquartered in Carson City, Nevada, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.

Where is Biovie Inc. headquartered?

Biovie Inc. is headquartered in Carson City, Nevada, United States.

Is Biovie Inc. publicly traded?

Yes — Biovie Inc. is a publicly traded company. Its stock trades under the ticker symbol BIVI on the NASDAQ.

What does Biovie Inc. do?

Biovie Inc. is an American Pharmaceuticals company in the Health & Beauty sector.

When was Biovie Inc. founded?

Biovie Inc. was founded in 2007.

Explore

Similar companies

Browse all →